Drugs / BMS-986184
BMS-986184
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02864264 | Sep 2016 → Sep 2017 | ulcerative colitis | Bristol-Myers Squibb | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02864264 ↗ |
| Known as | BMS-986184 (IP10.44) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095268 ↗ |
| Known as | Human anti-ip-10 antibody | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095268 ↗ |
| Known as | IP10.44 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095268 ↗ |
| Route | Intravenous | “Single intravenous (IV) dose of BMS-986184” NCT02864264 ↗ |